If you wish to receive Everest Medicines Limited information by email, please choose your options for email notification, enter your email address and information below and click "Submit".
2021-03-31
VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON CHINA NMPA APPROVAL OF CLINICAL TRIAL APPLICATION TO EVALUATE TRODELVY® IN A PHASE 2 BASKET TRIAL FOR A VARIETY OF CANCERS WITH HIGH TROP-2 EXPRESSION
2021-03-22
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2020
2021-03-22
VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON ACCEPTANCE OF NEW DRUG APPLICATION BY CHINA NMPA FOR XERAVA FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN CHINA
2021-03-10
DATE OF BOARD MEETING
2021-03-05
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2021
2021-03-01
VOLUNTARY ANNOUNCEMENT SELECTION AS A CONSTITUENT OF CERTAIN INDEXES OF HANG SENG INDEXES COMPANY LIMITED
2021-02-18
VOLUNTARY ANNOUNCEMENT APPOINTMENT OF CHIEF COMMERCIAL OFFICER
2021-01-18
VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON AMENDED AGREEMENT WITH SPERO THERAPEUTICS
2021-01-06
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2020
2021-01-06
VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON APPROVAL OF CLINICAL TRIAL APPLICATION BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR PHASE 3 REGISTRATION TRIAL OF SACITUZUMAB GOVITECAN-HZIY FOR METASTATIC UROTHELIAL CANCER
